Norris Medicines Intrinsic Value
NORRIS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Revenue Multiple Method | revenue | ₹5.60 | ₹5.04 - ₹6.16 | -62.7% | Revenue/Share: ₹7.00, P/S: 0.8x |
| Simple DCF (5Y) | dcf | ₹9.28 | ₹7.42 - ₹11.14 | -38.1% | CF Growth: 5.0%, Discount: 15% |
Want to compare with current market value? Check NORRIS share price latest .
Valuation Comparison Chart
NORRIS Intrinsic Value Analysis
What is the intrinsic value of NORRIS?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Norris Medicines (NORRIS) is ₹9.28 (median value). With the current market price of ₹15.00, this represents a -38.1% variance from our estimated fair value.
The valuation range spans from ₹5.60 to ₹9.28, indicating ₹5.60 - ₹9.28.
Is NORRIS undervalued or overvalued?
Based on our multi-method analysis, Norris Medicines (NORRIS) appears to be trading above calculated value by approximately 38.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.32 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | -0.93 | Industry Standard: <0.5 | Below 0.5 | Indicates financial leverage level |
| Return on Equity | 13.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | -8.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.50x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Norris Medicines
Additional stock information and data for NORRIS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |